Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors

PURPOSE: Peptide drugs for antineoplastic therapies usually have low oral bioavailability and short in vivo half-lives, requiring less preferred delivery methods. Lanreotide depot is a sustained-release somatostatin analog (SSA) formulation produced via an innovative peptide self-assembly method. La...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolin, Edward M., Manon, Amandine, Chassaing, Christophe, Lewis, Andy, Bertocchi, Laurent, Richard, Joel, Phan, Alexandria T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138269/
https://www.ncbi.nlm.nih.gov/pubmed/27619395
http://dx.doi.org/10.1007/s12029-016-9866-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138269/
https://www.ncbi.nlm.nih.gov/pubmed/27619395
http://dx.doi.org/10.1007/s12029-016-9866-9

Ejemplares similares